-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, OS1MppxL/Pf/Ucgx8inSil8V3hUDT2ouGNZUmssuCoe97W+pC2nLHA/hHmARVhsf TDO00e3Zxh4MlyzBgs+9Hw== 0000950133-96-000208.txt : 19960318 0000950133-96-000208.hdr.sgml : 19960318 ACCESSION NUMBER: 0000950133-96-000208 CONFORMED SUBMISSION TYPE: SC 13D/A PUBLIC DOCUMENT COUNT: 3 FILED AS OF DATE: 19960315 SROS: NONE GROUP MEMBERS: BB BIOTECH AG GROUP MEMBERS: BIOTECH FOCUS S.A. GROUP MEMBERS: BIOTECH INVEST S.A. GROUP MEMBERS: BIOTECH TARGET S.A. SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: BIOGEN INC CENTRAL INDEX KEY: 0000714655 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 043002117 STATE OF INCORPORATION: MA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-35348 FILM NUMBER: 96535057 BUSINESS ADDRESS: STREET 1: 14 CAMBRIDGE CTR CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 6176792000 MAIL ADDRESS: ZIP: 00000 FORMER COMPANY: FORMER CONFORMED NAME: BIOGEN NV DATE OF NAME CHANGE: 19880622 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: BB BIOTECH AG CENTRAL INDEX KEY: 0000924223 STANDARD INDUSTRIAL CLASSIFICATION: UNKNOWN SIC - 0000 [0000] STATE OF INCORPORATION: DC FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D/A BUSINESS ADDRESS: STREET 1: C/O BAKER & MCKENZIE STREET 2: 815 CONNECTICUT AVENUE, NW CITY: WASHINGTON STATE: DC ZIP: 20006 BUSINESS PHONE: 2028351882 MAIL ADDRESS: STREET 1: C/O BAKER & MCKENZIE STREET 2: 815 CONNECTICUT AVENUE NW CITY: WASHINGTON STATE: DC ZIP: 20006 SC 13D/A 1 BIOGEN, INC. SCHEDULE 13D, AMENDMENT 2. 1 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 2)* Under the Securities Exchange Act of 1934 BIOGEN,INC. ----------- (Name of Issuer) COMMON STOCK ------------ (Title of Class of Securities) 090597105 --------- (CUSIP Number) Daniel Schlatter Copy to: Daniel L. Goelzer, Esq. Theaterstrasse 12, Baker & McKenzie 8024 Zurich, CH/Switzerland 815 Connecticut Ave., N.W. 41-1-267-67-67 Washington, D.C. 20006 ----------------------------------------------------------------- (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) February 23, 1996 ----------------- (Date of Event which Requires Filing of this Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(b)(3) or (4), check the following box / /. Check the following box if a fee is being paid with the statement / /. (A fee is not required only if the reporting person: (1) has a previous statement on file reporting beneficial ownership of more than five percent of the class of securities described in Item 1; and (2) has filed no amendment subsequent thereto reporting beneficial ownership of five percent or less of such class.) (See Rule 13d-7.) Note: Six copies of this statement, including all exhibits, should be filed with the Commission. See Rule 13d-1(a) for other parties to whom copies are to be sent. *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). Page 1 of 7 Pages 2 CUSIP No. 090597105 - -------------------------------------------------------------------------------- (1) Name of Reporting Person S.S. or I.R.S. Identification No. of Above Person BB Biotech AG - -------------------------------------------------------------------------------- (2) Check the Appropriate Box if a Member (a) / / of a Group (See Instructions) (b) /x/ - -------------------------------------------------------------------------------- (3) SEC Use Only - -------------------------------------------------------------------------------- (4) Source of Funds (See Instructions) WC - -------------------------------------------------------------------------------- (5) Check Box if Disclosure of Legal Proceedings / / is Required Pursuant to Item 2(d) or 2(e) - -------------------------------------------------------------------------------- (6) Citizenship or Place of Organization Switzerland - -------------------------------------------------------------------------------- Number of Shares (7) Sole Voting Power: Beneficially Owned 0 by Each Reporting ------------------------------ Person With (8) Shared Voting Power 411,100 ------------------------------ (9) Sole Dispositive Power 0 ------------------------------ (10) Shared Dispositive Power 411,100 ------------------------------ - -------------------------------------------------------------------------------- (11) Aggregate Amount Beneficially Owned by Each Reporting Person 411,100 shares - -------------------------------------------------------------------------------- (12) Check Box if the Aggregate Amount in Row (11) / / Excludes Certain Shares (See Instructions) - -------------------------------------------------------------------------------- (13) Percent of Class Represented by Amount in Row (11) 1.12% - -------------------------------------------------------------------------------- (14) Type of Reporting Person (See Instructions) HC, CO - -------------------------------------------------------------------------------- Page 2 of 7 Pages 3 CUSIP No. 090597105 - -------------------------------------------------------------------------------- (1) Name of Reporting Person S.S. or I.R.S. Identification No. of Above Person Biotech Invest S.A. - -------------------------------------------------------------------------------- (2) Check the Appropriate Box if a Member (a) / / of a Group (See Instructions) (b) /x/ - -------------------------------------------------------------------------------- (3) SEC Use Only - -------------------------------------------------------------------------------- (4) Source of Funds (See Instructions) WC - -------------------------------------------------------------------------------- (5) Check Box if Disclosure of Legal Proceedings / / is Required Pursuant to Item 2(d) or 2(e) - -------------------------------------------------------------------------------- (6) Citizenship or Place of Organization Panama - -------------------------------------------------------------------------------- Number of Shares (7) Sole Voting Power Beneficially Owned 0 by Each Reporting ----------------------------- Person With (8) Shared Voting Power 0 ----------------------------- (9) Sole Dispositive Power 0 ----------------------------- (10) Shared Dispositive Power 0 ----------------------------- - -------------------------------------------------------------------------------- (11) Aggregate Amount Beneficially Owned by Each Reporting Person None - -------------------------------------------------------------------------------- (12) Check Box if the Aggregate Amount in Row (11) / / Excludes Certain Shares (See Instructions) - -------------------------------------------------------------------------------- (13) Percent of Class Represented by Amount in Row (11) None - -------------------------------------------------------------------------------- (14) Type of Reporting Person (See Instructions) CO - -------------------------------------------------------------------------------- Page 3 of 7 Pages 4 CUSIP No. 090597105 - -------------------------------------------------------------------------------- (1) Name of Reporting Person S.S. or I.R.S. Identification No. of Above Person Biotech Focus S.A. - -------------------------------------------------------------------------------- (2) Check the Appropriate Box if a Member (a) / / of a Group (See Instructions) (b) /x/ - -------------------------------------------------------------------------------- (3) SEC Use Only - -------------------------------------------------------------------------------- (4) Source of Funds (See Instructions) WC - -------------------------------------------------------------------------------- (5) Check Box if Disclosure of Legal Proceedings / / is Required Pursuant to Item 2(d) or 2(e) - -------------------------------------------------------------------------------- (6) Citizenship or Place of Organization Panama - -------------------------------------------------------------------------------- Number of Shares (7) Sole Voting Power Beneficially Owned 411,100 by Each Reporting ----------------------------- Person With (8) Shared Voting Power 0 ----------------------------- (9) Sole Dispositive Power 411,100 ----------------------------- (10) Shared Dispositive Power 0 ----------------------------- - -------------------------------------------------------------------------------- (11) Aggregate Amount Beneficially Owned by Each Reporting Person 411,100 shares - -------------------------------------------------------------------------------- (12) Check Box if the Aggregate Amount in Row (11) / / Excludes Certain Shares (See Instructions) - -------------------------------------------------------------------------------- (13) Percent of Class Represented by Amount in Row (11) 1.12% - -------------------------------------------------------------------------------- (14) Type of Reporting Person (See Instructions) CO - -------------------------------------------------------------------------------- Page 4 of 7 Pages 5 CUSIP No. 090597105 - -------------------------------------------------------------------------------- (1) Name of Reporting Person S.S. or I.R.S. Identification No. of Above Person Biotech Target S.A. - -------------------------------------------------------------------------------- (2) Check the Appropriate Box if a Member (a) / / of a Group (See Instructions) (b) /x/ - -------------------------------------------------------------------------------- (3) SEC Use Only - -------------------------------------------------------------------------------- (4) Source of Funds (See Instructions) WC - -------------------------------------------------------------------------------- (5) Check Box if Disclosure of Legal Proceedings / / is Required Pursuant to Item 2(d) or 2(e) - -------------------------------------------------------------------------------- (6) Citizenship or Place of Organization Panama - -------------------------------------------------------------------------------- Number of Shares (7) Sole Voting Power Beneficially Owned 0 by Each Reporting ----------------------------- Person With (8) Shared Voting Power 0 ----------------------------- (9) Sole Dispositive Power 0 ----------------------------- (10) Shared Dispositive Power 0 ----------------------------- - -------------------------------------------------------------------------------- (11) Aggregate Amount Beneficially Owned by Each Reporting Person None - -------------------------------------------------------------------------------- (12) Check Box if the Aggregate Amount in Row (11) / / Excludes Certain Shares (See Instructions) - -------------------------------------------------------------------------------- (13) Percent of Class Represented by Amount in Row (11) None - -------------------------------------------------------------------------------- (14) Type of Reporting Person (See Instructions) CO - -------------------------------------------------------------------------------- Page 5 of 7 Pages 6 SCHEDULE 13D This Amendment No. 2 reflects open market sales of 2,428,900 shares of common stock, par value $.01 per share ("Common Stock"), of Biogen, Inc. ("Biogen") by (i) BB Biotech AG, a Swiss corporation ("BB Biotech"), (ii) Biotech Invest S.A., a Panamanian corporation ("Biotech Invest"), (iii) Biotech Focus, S.A., a Panamanian corporation ("Biotech Focus") and (iv) Biotech Target S.A., a Panamanian corporation ("Biotech Target", Biotech Invest, Biotech Focus and Biotech Target are collectively referred to as the "Biotech Subsidiaries"). As of February 23, 1996, BB Biotech and the Biotech Subsidiaries ceased to have beneficial ownership of more than 5 percent of the Common Stock of Biogen. ITEM 5. INTEREST IN SECURITIES OF THE ISSUER ITEMS 5(a), (b), (c) AND (e) ARE AMENDED IN THEIR ENTIRETY TO READ AS FOLLOWS: (a) The Biotech Subsidiaries collectively held 2,840,000 shares, or approximately 8.25 percent, of Biogen Common Stock on July 6, 1994 (the filing date of Amendment No. 1 to Schedule 13D). As of February 23, 1996, the Biotech Subsidiaries held 1,693,400 shares, or approximately 4.61 percent, of Biogen Common Stock. Since that time, the Biogen Subsidiaries have sold shares in the open market to reduce their holdings to 411,100 shares, or approximately 1.12 percent of the outstanding Common Stock of Biogen as of March 7, 1996. As a result, BB Biotech may be deemed to be the indirect beneficial owner of the 411,100 shares of Biogen Common Stock held directly in the aggregate by the Biotech Focus as of March 7, 1996, which represents approximately 1.12 percent of the outstanding shares of Biogen Common Stock. No shares of Biogen Common Stock are directly owned by BB Biotech. To the best knowledge of BB Biotech and the Biotech Subsidiaries, no director or executive officer of BB Biotech or the Biotech Subsidiaries owns any shares of Biogen Common Stock. (b) The number of shares of Biogen Common Stock to which there is sole power to vote or to direct the vote, shares power to vote or to direct the vote, sole power to dispose or to direct the disposition, or shared power to dispose or direct the disposition is set forth in the cover pages and such information is incorporated herein by reference. BB Biotech, through its ownership of the Biotech Subsidiaries, may be deemed to beneficially own the shares of Biogen Common Stock within the meaning of Regulation 13D under the Exchange Act, and may be deemed to share with the Biotech Subsidiaries the power to vote or direct the vote of and the power to dispose of or direct the disposition of the aggregate 411,100 shares of Biogen Common Stock held by Biotech Focus. BB Biotech hereby expressly declares that the filing of this statement shall not be construed as an admission that it is, for purposes of Section 13(d) of the Exchange Act, the beneficial owner of the shares of Biogen Common Stock held by the Biotech Subsidiaries. (c) A summary of transactions in Biogen Common Stock effected by the Biotech Subsidiaries during the past sixty days is attached hereto as Exhibit A and such information is incorporated herein by reference. (e) As of February 23, 1996, BB Biotech and the Biotech Subsidiaries ceased to have beneficial ownership of more than 5 percent of the Common Stock of Biogen. ITEM 7. MATERIAL TO BE FILED AS EXHIBITS ITEM 7 IS HEREBY AMENDED TO ADD THE FOLLOWING: Exhibit H: Agreement by and among BB Biotech, Biotech Invest, Biotech Focus, and Biotech Target with respect to the filing of this Amendment No. 2 to a statement on Schedule 13D dated March 13, 1996. Page 6 of 7 Pages 7 SIGNATURES After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. BB BIOTECH AG Date: March 13, 1996 By:/s/ Daniel Schlatter ---------------------------------------- Name: Daniel Schlatter Title: Counsel By:/s/ Dr. Ernst Mueller-Moehl ---------------------------------------- Name: Dr. Ernst Mueller-Moehl BIOTECH INVEST, S.A. Date: March 13, 1996 By:/s/ Daniel Schlatter ---------------------------------------- Name: Daniel Schlatter Title: Counsel BIOTECH FOCUS, S.A. Date: March 13, 1996 By:/s/ Daniel Schlatter ---------------------------------------- Name: Daniel Schlatter Title: Counsel BIOTECH TARGET, S.A. Date: March 13, 1996 By:/s/ Daniel Schlatter ---------------------------------------- Name: Daniel Schlatter Title: Counsel Page 7 of 7 Pages 8 EXHIBIT INDEX ------------- EXHIBIT 99.A - AMENDED TRANSACTION SUMMARY. EXHIBIT 99.H - JOINT FILING AGREEMENT. EX-99.A 2 AMENDED TRANSACTION SUMMARY. 1 Exhibit A EXHIBIT A IS HEREBY AMENDED TO ADD THE FOLLOWING SUMMARY OF TRANSACTIONS IN BIOGEN COMMON STOCK EFFECTED BY THE BIOTECH SUBSIDIARIES FROM JANUARY 17, 1996 THROUGH MARCH 7, 1996.
------------------------------------------------------------------------------------------------------------------------------- DATE TYPE OF TRANSACTION, NUMBER, BENEFICIALLY TOTAL SHARES PERCENT CLASS AND PRICE OF SHARES OWNED OUTSTANDING OF OUTSTANDING SHARES OWNED ------------------------------------------------------------------------------------------------------------------------------- January 17, Sale of 10,000 shares of Common Stock. 2,100,000 36,720,000 5.72% 1996 shares of Common Stock ------------------------------------------------------------------------------------------------------------------------------- January 22, Sale of 30,000 shares of Common Stock. 2,070,000 36,720,000 5.64% 1996 shares of Common Stock ------------------------------------------------------------------------------------------------------------------------------- January 29, Sale of 50,000 shares of Common Stock. 2,020,000 36,720,000 5.50% 1996 shares of Common Stock ------------------------------------------------------------------------------------------------------------------------------- January 30, Sale of 12,000 shares of Common Stock. 2,008,000 36,720,000 5.47% 1996 shares of Common Stock ------------------------------------------------------------------------------------------------------------------------------- January 31, Sale of 8,000 shares of Common Stock. 2,000,000 36,720,000 5.45% 1996 shares of Common Stock ------------------------------------------------------------------------------------------------------------------------------- February 12, Sale of 80,000 shares of Common Stock. 1,920,000 36,720,000 5.23% 1996 shares of Common Stock ------------------------------------------------------------------------------------------------------------------------------- February 20, Sale of 50,000 shares of Common Stock. 1,870,000 36,720,000 5.09% 1996 shares of Common Stock ------------------------------------------------------------------------------------------------------------------------------- February 21, Sale of 26,000 shares of Common Stock; purchase 1,901,000 36,720,000 5.18% 1996 of 57,000 shares of Common Stock. shares of Common Stock ------------------------------------------------------------------------------------------------------------------------------- February 23, Sale of 207,600 shares of Common Stock. 1,693,400 36,720,000 4.61% 1996 shares of Common Stock -------------------------------------------------------------------------------------------------------------------------------
2
------------------------------------------------------------------------------------------------------------------------------- DATE TYPE OF TRANSACTION, NUMBER, BENEFICIALLY TOTAL SHARES PERCENT CLASS AND PRICE OF SHARES OWNED OUTSTANDING OF OUTSTANDING SHARES OWNED ------------------------------------------------------------------------------------------------------------------------------- February 26, Sale of 90,000 shares of Common Stock. 1,603,400 36,720,000 4.37% 1996 shares of Common Stock ------------------------------------------------------------------------------------------------------------------------------- February 27, Sale of 167,300 shares of Common Stock. 1,436,100 36,720,000 3.91% 1996 shares of Common Stock ------------------------------------------------------------------------------------------------------------------------------- February 28, Sale of 67,500 shares of Common Stock. 1,368,600 36,720,000 3.73% 1996 shares of Common Stock ------------------------------------------------------------------------------------------------------------------------------- February 29, Sale of 93,000 shares of Common Stock. 1,274,800 36,720,000 3.47% 1996 shares of Common Stock ------------------------------------------------------------------------------------------------------------------------------- March 1, 1996 Sale of 61,000 shares of Common Stock. 1,213,800 36,720,000 3.31% shares of Common Stock ------------------------------------------------------------------------------------------------------------------------------- March 4, 1996 Sale of 64,200 shares of Common Stock. 1,149,600 36,720,000 3.13% shares of Common Stock ------------------------------------------------------------------------------------------------------------------------------- March 5, 1996 Sale of 12,200 shares of Common Stock; purchase 1,087,900 36,720,000 2.96% of 67,700 shares of Common Stock. shares of Common Stock ------------------------------------------------------------------------------------------------------------------------------- March 6, 1996 Sale of 86,800 shares of Common Stock. 1,001,100 36,720,000 2.73% shares of Common Stock ------------------------------------------------------------------------------------------------------------------------------- March 7, 1996 Sale of 590,000 shares of Common Stock. 411,100 36,720,000 1.12% shares of Common Stock -------------------------------------------------------------------------------------------------------------------------------
EX-99.H 3 JOINT FILING AGREEMENT. 1 Exhibit H JOINT FILING AGREEMENT We, the undersigned, hereby express our agreement that the attached Amendment No. 2 to a statement on Schedule 13D for the event dated February 23, 1996, is filed on behalf of each of the undersigned. Date: March 13, 1996 BB BIOTECH AG By: /s/ Daniel Schlatter ------------------------------------ Name: Daniel Schlatter Title: Counsel By: /s/ Dr. Ernst Mueller-Moehl ------------------------------------ Name: Dr. Ernst Mueller-Moehl BIOTECH INVEST, S.A. By: /s/ Daniel Schlatter ------------------------------------ Name: Daniel Schlatter Title: Counsel BIOTECH FOCUS, S.A. By: /s/ Daniel Schlatter ------------------------------------ Name: Daniel Schlatter Title: Counsel BIOTECH TARGET, S.A. By: /s/ Daniel Schlatter ------------------------------------ Name: Daniel Schlatter Title: Counsel -----END PRIVACY-ENHANCED MESSAGE-----